Ongoing clinical study

Study to evaluate “best of” radiotherapy compared to “best of” surgery in patients with oropharyngeal carcinoma (best of)”

Oropharyngeal squamous cell carcinoma (OPSCC) develops in the soft palate, tonsils, base of the tongue, pharyngeal wall and vallecula. Most patients with early-stage OPSCC are usually cured. Depending on the indication, early-stage OPSCC can be successfully treated with primary surgery including neck dissection or with definitive radiotherapy.

Aim of the study

The study investigates the extent to which surgery or radiotherapy influences the recovery of normal swallowing function after treatment of a malignant tumor in the throat at an early stage. Both forms of treatment are already being used successfully today, but so far there has been no clarification as to which therapy is better.

Who can participate?

Patients with oropharyngeal squamous cell carcinoma (OPSCC)

Procedure

If you agree to participate, your doctor will carry out a series of examinations and tests to find out whether you are eligible for the study. The participants are divided into 2 groups. Each group will either undergo surgery or receive radiotherapy. During the study period, you will be asked to complete regular questionnaires about your swallowing function, your financial situation and your general quality of life. During the clinical follow-up and imaging procedures, your health will also be monitored according to standard practice.

Compensation

None

Original study name

Phase III study to evaluate the "best" radiotherapy compared to the "best" surgery (transoral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal carcinoma, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma

BASEC number

2017-01600

Financial support from

European Organization forResearch and Treatment of Cancer (EORTC)

This study is no longer seeking participants. For general questions and further information about the study, please contact us at the address provided.